Bristol-Myers Squibb

Company BMY

Last mentioned: Feb 19, 2026

Stories mentioning Bristol-Myers Squibb 2

markets Bullish

JIA Market Set for 5.6% CAGR Growth Through 2036 as Biologics Drive Expansion

The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.

4 sources
pharma Bullish

JIA Market to Reach $2.3B as Biologic Innovation Drives 5.6% CAGR through 2036

The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.

4 sources